Table 1.
Patient demographics and mortality by receipt of immunotherapy.
| Variables | Total (N = 176) |
on Immunotherapy (N = 39) | Not on Immunotherapy (N = 137) | p Value |
|---|---|---|---|---|
| Year of cancer diagnosis | <0.001 ‡ | |||
| 2016 | 4 (2.3) | 0 | 4 (2.9) | |
| 2017 | 26 (14.8) | 6 (15.4) | 20 (14.6) | |
| 2018 | 50 (28.4) | 3 (7.7) | 47 (34.3) | |
| 2019 | 48 (27.3) | 11 (28.2) | 37 (27.0) | |
| 2020 | 30 (17.0) | 8 (20.5) | 22 (16.1) | |
| 2021 | 18 (10.2) | 11 (28.2) | 7 (5.1) | |
| Year of surgery | <0.001 ‡ | |||
| 2017 | 11 (6.3) | 1 (2.6) | 10 (7.3) | |
| 2018 | 47 (26.7) | 7 (17.9) | 40 (29.2) | |
| 2019 | 50 (28.4) | 9 (23.1) | 41 (29.9) | |
| 2020 | 38 (21.6) | 6 (15.4) | 32 (23.4) | |
| 2021 | 30 (17.0) | 16 (41.0) | 14 (10.2) | |
| Age | 0.282 † | |||
| Mean ± standard deviation | 65.1 ± 9.8 | 63.6 ± 11.4 | 65.5 ± 9.3 | |
| Minimum-Maximum | 24.0–83.0 | 24.0–83.0 | 30.0–83.0 | |
| Sex | 0.500 ‡ | |||
| Female | 34 (19.3) | 9 (23.1) | 25 (18.2) | |
| Male | 142 (80.7) | 30 (76.9) | 112 (81.8) | |
| Race/ethnicity | 0.072 § | |||
| White | 122 (69.3) | 23 (59.0) | 99 (72.3) | |
| African-American | 6 (3.4) | 2 (5.1) | 4 (2.9) | |
| Hispanic | 17 (9.7) | 4 (10.3) | 13 (9.5) | |
| Asian/Pacific Islander | 23 (13.1) | 5 (12.8) | 18 (13.1) | |
| Native American/Multiracial/Other/Unknown | 8 (4.5) | 5 (12.8) | 3 (2.2) | |
| Body mass index | 0.055 † | |||
| Mean ± standard deviation | 27.0 ± 5.1 | 25.6 ± 4.9 | 27.4 ± 5.2 | |
| Smoking history | 0.976 ‡ | |||
| Yes | 13 (7.4) | 3 (7.7) | 10 (7.3) | |
| Never | 61 (34.7) | 14 (35.9) | 47 (34.3) | |
| Former Smoker | 102 (58.0) | 22 (56.4) | 80 (58.4) | |
| Alcohol abuse | 0.103 § | |||
| 0 | 161 (91.5) | 33 (84.6) | 128 (93.4) | |
| 1 | 15 (8.5) | 6 (15.4) | 9 (6.6) | |
| Charlson Comorbidity Index | 0.727 ‡ | |||
| 0-3 | 27 (15.3) | 7 (17.9) | 20 (14.6) | |
| 4-6 | 34 (19.3) | 6 (15.4) | 28 (20.4) | |
| 7+ | 115 (65.3) | 26 (66.7) | 89 (65.0) | |
| Neoadjuvant chemotherapy/radiation | 0.075 § | |||
| 0 | 13 (7.4) | 0 | 13 (9.5) | |
| 1 | 163 (92.6) | 39 (100) | 124 (90.5) | |
| Operative duration (in minutes) | 0.695 † | |||
| Mean ± standard deviation | 225.0 ± 70.1 | 221.1 ± 73.6 | 226.1 ± 69.4 | |
| Cancer clinical stage | 0.002 ‡ | |||
| I | 57 (32.4) | 5 (12.8) | 52 (38.0) | |
| II | 41 (23.3) | 7 (17.9) | 34 (24.8) | |
| III | 47 (26.7) | 14 (35.9) | 33 (24.1) | |
| IV | 31 (17.6) | 13 (33.3) | 18 (13.1) | |
| Early vs. late clinical stage | <0.001 ‡ | |||
| I/II | 98 (55.7) | 12 (30.8) | 86 (62.8) | |
| III/IV | 78 (44.3) | 27 (69.2) | 51 (37.2) | |
| Histology | 0.866 ‡ | |||
| Adenocarcinoma | 154 (87.5) | 34 (87.2) | 120 (87.6) | |
| Squamous | 20 (11.4) | 5 (12.8) | 15 (10.9) | |
| Other | 2 (1.1) | 0 | 2 (1.5) | |
| Adjuvant chemotherapy/radiation | <0.001 ‡ | |||
| 0 | 111 (63.1) | 15 (38.5) | 96 (70.1) | |
| 1 | 65 (36.9) | 24 (61.5) | 41 (29.9) | |
| 90 day mortality | 0.351 § | |||
| 0 | 169 (96.0) | 39 (100) | 130 (94.9) | |
| 1 | 7 (4.0) | 0 | 7 (5.1) | |
| 1 year mortality | ||||
| 0 | 147 (83.5) | 35 (89.7) | 112 (81.8) | 0.235 ‡ |
| 1 | 29 (16.5) | 4 (10.3) | 25 (18.2) |
† Two-sample t-test; ‡ Chi-square test; § Fisher’s exact test.